HOOKIPA Pharma Inc. (HOOK) Prices 3.4M Share Common Offering at $11.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
After-Hours Stock Movers 12/08: (RCKT) (PRPH) (SDC) Higher; (GME) (DCTH) (TALO) Lower (more...)
December 8, 2020 5:41 PM ESTToday's After-Hours Stock Movers:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) 33.4% HIGHER; announces preliminary data from its open-label, Phase 1 clinical trial of RP-A501, the Companys adeno-associated viral vector (AAV)-based gene therapy candidate expressing LAMP2B for the treatment of Danon Disease. Danon Disease is a rare X-linked inherited disorder caused by genetic mutations in the LAMP2 gene resulting in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to severe and frequently fatal cardiomyopathy. Preliminary data from patients in the low dose... More
HOOKIPA Pharma Inc. (HOOK) to Offer Common and Preferred Stock
December 8, 2020 4:02 PM ESTHOOKIPA Pharma Inc. (Nasdaq: HOOK) intends to offer and sell shares of its common stock and shares of Series A convertible preferred stock in an underwritten public offering (the Offering). HOOKIPA also intends to grant the underwriters a 30-day option to purchase up to an... More
HOOKIPA Pharma Inc. (HOOK) PT Raised to $28 at SVB Leerink, Following Clinical Trial update
December 7, 2020 2:17 PM ESTSVB Leerink analyst Andrew S. Berens raised the price target on HOOKIPA Pharma Inc. (NASDAQ: HOOK) to $28.00 (from $23.00) while maintaining a Outperform rating.
... MoreHOOKIPA Pharma Inc. (HOOK) PT Raised to $23 at Truist Securities
December 7, 2020 12:34 PM ESTTruist Securities analyst Asthika Goonewardene raised the price target on HOOKIPA Pharma Inc. (NASDAQ: HOOK) to $23.00 (from $21.00) while maintaining a Buy rating.
Positive First IO Read-out Signals Undercurrent of More Good Things to Come... MorePre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...)
December 7, 2020 9:26 AM ESTToday's Pre-Open Stock Movers
Eastman Kodak Company (NYSE: KODK) 72% HIGHER; news that federal regulators found no wrongdoing in getting a loan from the government.
Kura Oncology, Inc. (Nasdaq: KURA) 16.9% HIGHER; announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial of the Companys oral, potent and selective menin inhibitor, KO-539, including single-agent activity in genetically defined subgroups of patients with relapsed or refractory acute myeloid leukemia (AML).
Matinas BioPharma Holdings, Inc. (NYSE:... More
HOOKIPA Pharma Inc. (HOOK) Reports Promising Anti-Tumor Activity & Favorable Tolerability for Phase 1 Monotherapy Data of HB-201 for Treatment of Advanced HPV16+ Cancers
December 7, 2020 6:06 AM ESTHOOKIPA Pharma Inc. (NASDAQ: HOOK) today announced positive interim Phase 1 data on HB-201, its replicating monotherapy for the treatment of HPV16+ cancers. The results are from the initial dose escalation cohorts of an ongoing Phase 1/2 clinical trial (NCT04180215) evaluating HB- 201 as therapy for patients with advanced HPV16+ metastatic cancers. HOOKIPA will host a conference call and live audio webcast today at 8:30am EST.
These interim data support proof of concept for HB-201 monotherapy as a new immunotherapy for a difficult-to-treat patient population with multiple prior treatment... More
